Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Intervertebral disc degeneration? 144 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 144 reports of Intervertebral disc degeneration have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.1% of all adverse event reports for SECUKINUMAB.

144
Reports of Intervertebral disc degeneration with SECUKINUMAB
0.1%
of all SECUKINUMAB reports
2
Deaths
20
Hospitalizations

How Dangerous Is Intervertebral disc degeneration From SECUKINUMAB?

Of the 144 reports, 2 (1.4%) resulted in death, 20 (13.9%) required hospitalization, and 6 (4.2%) were considered life-threatening.

Is Intervertebral disc degeneration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 144 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Intervertebral disc degeneration?

ADALIMUMAB (873) ALENDRONATE (339) ETANERCEPT (311) METHOTREXATE (308) EMTRICITABINE\TENOFOVIR DISOPROXIL (210) PREGABALIN (204) PREDNISONE (202) RITUXIMAB (200) OXYCODONE (184) SODIUM OXYBATE (178)

Which SECUKINUMAB Alternatives Have Lower Intervertebral disc degeneration Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Intervertebral disc degeneration Reports All Drugs Causing Intervertebral disc degeneration SECUKINUMAB Demographics